Anivive Lifesciences, a California-based pharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) Center for Veterinary Medicine has granted full approval for Laverdia (verdinexor tablets), which the company says marks a major advancement in canine lymphoma the treatment.

According to Anivive, Laverdia is the first FDA-approved oral, at-home treatment for lymphoma in dogs, designed to give veterinarians and pet owners a safe, effective, and more accessible option for managing one of the most common cancers in dogs.

Laverdia also marks the first FDA-approved product to complete Anivive's technology-enabled development cycle. AniviveSELECT, the company's AI drug repurposing platform, identified and prioritised verdinexor for canine lymphoma by connecting evidence from human medicine with veterinary disease biology. AniviveTRIAL then helped identify, match and recruit dogs for the nationwide pivotal study, contributing approximately 40% of enrollment, accelerating the path to approval.

Anvive stated that Laverdia works as an XPO1 inhibitor by selectively inhibiting nuclear export proteins involved in cancer cell survival, a mechanism developed in veterinary oncology by Anivive's scientific partners. In clinical evaluations, the treatment is claimed to have demonstrated promising results with a well-tolerated safety profile.

Building on the momentum of the US approval, Anivive said it is pursuing approvals for Laverdia in Australia, Brazil, Canada, Europe, Japan and the UK. Additionally, Anivive is investigating verdinexor for other canine and feline cancers, and as a potential antiviral in veterinary medicine, and continues to expand distribution of its SearchLight DNATM next-generation genomic sequencing test for pet cancers.